Editor’s note

Pharma companies are likely to spend higher on R&D but without the high returns

A quid pro quo, of an easing drug price control, in exchange for increased investments in manufacturing, backward integration…

Pfizer's loss will be the gain of numerous pharma companies and CROs as they look to hire from this talent pool The new year…

e-pharmacies cannot be considered a mere extension of the e-commerce boom, simply because the patient cannot tell the difference…

If 2018 was defined by Ayushman Bharat, what will define 2019? As we wind up one year and gear up for the next, I wonder how CEOs…

Merely having an HIV/AIDS Act or NACO’s strategic plan will not help because as NACO’s Director Alok Saxena puts it, human…

Smart companies will focus on discovering avenues which lead to long-term sustainable growth

While the Competition Commission of India (CCI) note appreciates 'legitimate public policy objectives', it tries to determine the…

With saturation in export markets and rising regulatory constraints, will we see a refocus on the domestic market, prodded by…

Framing regulations is one thing, interpreting and implementing them quite another saga, allowing repeat offenders like Biomed to…